Table 1.
Clinical trials targeting the NLRP3 inflammasome signaling pathway
| Drugs | Diseases | Mechanism | Phase | Trial identifier |
|---|---|---|---|---|
| Anakinra | Metastatic breast cancer | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 1 | NCT01802970 |
| Anakinra | Metastatic colorectal cancer | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 2 | NCT02090101 |
| Anakinra/dexamethasone acetate | Multiple myeloma and plasma cell neoplasm | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 2 | NCT00635154 |
| Anakinra/dexamethasone | Indolent plasma cell myeloma, plasma cell myeloma | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 1 | NCT02492750 |
| Anakinra | Heart failure with normal ejection fraction | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 2 | NCT02173548 |
| Anakinra | Heart failure | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 3 | NCT01936909 |
| Anakinra | Heart failure | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 3 | NCT01936844 |
| Anakinra | ST segment elevation, acute myocardial infarction | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 3 | NCT00789724 |
| Anakinra | Heart failure | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 2 | NCT01300650 |
| Anakinra | Heart failure | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | N/A | NCT01542502 |
| Anakinra | Acute myocardial infarction, heart failure | Antagonist to IL-1 receptor (blocking both IL-1α and IL-1β) | Phase 2 | NCT01175018 |
| Canakinumab | Non-small-cell lung cancer | Antibody targeting IL-1β | Phase 3 | NCT03626545 |
| Canakinumab | Non-small-cell lung cancer | Antibody targeting IL-1β | Phase 3 | NCT03631199 |
| Canakinumab | HIV, cardiovascular disease | Antibody targeting IL-1β | Phase 2 | NCT02272946 |
| Canakinumab | Type 2 diabetes | Antibody targeting IL-1β | Phase 2 | NCT01068860 |
| Canakinumab | Type 2 diabetes | Antibody targeting IL-1β | Phase 2 | NCT00605475 |
| Memantine/Dopamine receptor-agonists | Neurodegenerative disease | NLRP3 inhibition by blocking P2X7 receptor | N/A | NCT03918616 |
| MCC950 | Head and neck squamous cell carcinoma | Targeting NLRP3 | N/A | N/A |
| BOT-4-one | Lymphoma | Targeting NLRP3 | N/A | N/A |